I-antibiotics yangoku esetyenziswa kwiklinikhi, ukongeza kwi-neutralizing pathogens ekujoliswe kuyo nayo ilimaza ibhaktheriya enempilo emathunjini. Ukuphazamiseka kwi-gut microbiome kuneziphumo eziyityhefu kwisibindi, izintso kunye namanye amalungu. Lo ngumba oza kuqwalaselwa. Abaphandi baye bafumanisa i-lolamicin, umviwa we-antibiotic oye wafunyaniswa esebenza ngokuchasene nosulelo lwegram-negative ngaphandle kokuchaphazela impilo ye-gut microbiome kwizifundo zangaphambi kweklinikhi. Obu bubungqina bokuba i-antibiotics ebulala i-pathogenic microbes ngelixa igcina ibhaktheriya enenzuzo emathunjini inokuphuhliswa usulelo lwegram-negative. Inika ithemba lokujongana neengxaki ezinxulumene nokujoliswa okungakhethiyo kweebhaktheriya zegram-negative. Nangona kunjalo, iminyaka yophando olongezelelweyo iyafuneka ngaphambi kokuba ifike kwinqanaba lokusetyenziswa kweklinikhi.
Uninzi lwee-antibiotics lujolise kuphela kwiibhaktheriya ezinegram okanye lujolise kwiibhaktheriya ezinegram kunye negram. Ezinye ii-antibiotics ezikhethekileyo kwiibhaktheriya ezinegram (iibhaktheriya ezinegram zinomgangatho ophindwe kabini wokhuseleko eludongeni lweeseli zazo ezenza kube nzima ukuzibulala) zibulala neebhaktheriya ezinegram eziluncedo emathunjini. Ukuphazamiseka kwi-microbiome yamathumbu okudalwe ngaloo ndlela kufunyenwe kunemiphumo enobungozi/embi ngakumbi kwisibindi kunye nezintso. Yiyo loo nto kufuneka kuphuhliswe ii-antibiotics ezinokubulala iibhaktheriya ezine-pathogenic ngokukhetha ngelixa kugcinwe ezo ziluncedo. Njengoko kuxeliwe kwiphepha lophando lwakutshanje, izazinzulu ziye zavelisa enye ye-antibiotic ebizwa ngokuba yi-lolamicin efunyenwe ijolise ngokukhethekileyo kwiibhaktheriya ezine-gram ezinokubangela i-pathogenic ngokukhetha ngelixa kugcinwe ezo ziluncedo.
I-Lolamicin yi-inhibitor ye-Lol (indawo ye-lipoproteins) indlela, inkqubo ye-lipoprotein-transport efunyenwe ngokukodwa kwiibhaktheriya zegram-negative ezihluke kwi-genetically kwi-pathogenic kunye ne-bacteria enenzuzo.
Kwinkcubeko yeeseli, yayingenayo impembelelo exabisekileyo kwiibhaktheriya zegram-positive. Kwidosi eziphezulu, iye yanciphisa ukuya kutsho kwi-90% ye-E. coli enganyangekiyo ngamachiza amaninzi, i-K. pneumoniae kunye ne-E. cloacae Clinical isolates.
Ukulawulwa ngomlomo kwe-lolamicin kwiigundane ezine-septicemia enganyangekiyo ngamachiza okanye inyumoniya yahlangula i-100% yeempuku ezine-septicemia kunye ne-70% yeempuku ezinenyumoniya. Ngapha koko, ulawulo lwe-lolamicin aluzange lukhokelele kulo naluphi na utshintsho olukhulu ekubunjweni kwe-taxonomic yeebhaktheriya kwi-gut microbiome yeempuku ngexesha lonyango lweentsuku ezintathu okanye olu lulandelayo lweentsuku ezingama-28.
Ezi ziphumo zophando lwezilwanyana zangaphambi konyango ziyakhuthaza kwaye zinika ithemba lokujongana neengxaki ezinxulumene nokujoliswa ngokungakhethiyo kwiintsholongwane ezingeyo gram. Bubungqina bengcamango yokuba kunokwenzeka ukuphuhlisa ii-antibiotics ezijolise ngokukhethekileyo kwiintsholongwane ezinobungozi zegram ngelixa zikhusela iintsholongwane zamathumbu kuyo nayiphi na imiphumo emibi. Nangona kunjalo, kufuneka iminyaka yophando olongezelelekileyo ukwandisa iziphumo.
***
Iingxelo:
- Muñoz, KA, Ulrich, RJ, Vasan, AK et al. I-antibiotic ye-Gram-negative-selective egcina i-gut microbiome. Indalo 630, 429-436 (2024). Ipapashwe: 29 May 2024. DOI: https://doi.org/10.1038/s41586-024-07502-0
- IYunivesithi yase-Illinois Urbana-Champaign 2024. Iindaba zophando - I-antibiotic entsha ibulala ibhaktheriya ye-pathogenic, igcina iintsholongwane eziphilileyo zamathumbu. Ithunyelwe nge-29 kuMeyi 2024. Iyafumaneka e https://news.illinois.edu/view/6367/668002791
***
